Free Trial

Insider Selling: Heartflow (NASDAQ:HTFL) CEO Sells 38,900 Shares of Company Stock

Heartflow logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CEO John Farquhar sold 38,900 Heartflow shares at an average price of $49.57, generating approximately $1.93 million. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced his holdings by 12.08% to 283,014 shares.
  • Heartflow shares fell 1.7% to $49.46, although the stock remains near its 12-month high of $54.32 and has risen substantially from its $20.13 low. The company reported stronger-than-expected quarterly results, including $64.08 million in revenue, up 47.7% year over year.
  • Analysts maintain a generally positive view, with a consensus rating of “Moderate Buy” and an average price target of $46.25. However, the company remains unprofitable, with negative margins and analysts expecting a full-year loss of $0.75 per share.
  • Five stocks we like better than Heartflow.

Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) CEO John Farquhar sold 38,900 shares of Heartflow stock in a transaction on Monday, October 12th. The stock was sold at an average price of $49.57, for a total transaction of $1,928,273.00. Following the completion of the transaction, the chief executive officer owned 283,014 shares in the company, valued at $14,029,003.98. This trade represents a 12.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John C.M. Farquhar also recently made the following trade(s):

  • On Friday, September 11th, John Farquhar sold 3,890 shares of Heartflow stock. The shares were sold at an average price of $50.00, for a total transaction of $194,500.00.
  • On Thursday, September 10th, John Farquhar sold 35,010 shares of Heartflow stock. The shares were sold at an average price of $46.42, for a total value of $1,625,164.20.
  • On Friday, August 21st, John Farquhar sold 27,230 shares of Heartflow stock. The shares were sold at an average price of $50.00, for a total value of $1,361,500.00.
  • On Tuesday, August 18th, John Farquhar sold 32,676 shares of Heartflow stock. The stock was sold at an average price of $45.00, for a total value of $1,470,420.00.
  • On Friday, August 14th, John Farquhar sold 15,560 shares of Heartflow stock. The stock was sold at an average price of $39.06, for a total value of $607,773.60.
  • On Monday, August 10th, John Farquhar sold 22,562 shares of Heartflow stock. The shares were sold at an average price of $28.31, for a total value of $638,730.22.

Heartflow Trading Down 1.7%

HTFL traded down $0.86 during midday trading on Wednesday, reaching $49.46. The company's stock had a trading volume of 1,616,040 shares, compared to its average volume of 1,594,796. The stock has a market cap of $4.30 billion, a P/E ratio of -27.03 and a beta of 2.73. The company has a fifty day simple moving average of $45.96 and a 200 day simple moving average of $34.82. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $54.32.

Heartflow (NASDAQ:HTFL - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.15. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%. The company had revenue of $64.08 million for the quarter. The firm's quarterly revenue was up 47.7% on a year-over-year basis. Sell-side analysts expect that Heartflow, Inc. will post -0.75 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Robert W. Baird set a $45.00 target price on shares of Heartflow in a research report on Friday, August 14th. Wall Street Zen raised shares of Heartflow from a "hold" rating to a "buy" rating in a report on Saturday, October 3rd. Weiss Ratings upgraded shares of Heartflow from a "sell (e+)" rating to a "sell (d-)" rating in a report on Friday, August 7th. JPMorgan Chase & Co. boosted their price objective on shares of Heartflow from $35.00 to $45.00 and gave the stock an "overweight" rating in a report on Friday, August 14th. Finally, Stifel Nicolaus upped their price objective on shares of Heartflow from $40.00 to $45.00 and gave the company a "buy" rating in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Heartflow currently has an average rating of "Moderate Buy" and a consensus price target of $46.25.

Get Our Latest Research Report on Heartflow

Institutional Investors Weigh In On Heartflow

A number of institutional investors have recently bought and sold shares of HTFL. GAMMA Investing LLC grew its holdings in shares of Heartflow by 75.1% in the 3rd quarter. GAMMA Investing LLC now owns 641 shares of the company's stock worth $32,000 after purchasing an additional 275 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Heartflow during the 2nd quarter worth about $53,000. Essential Partners LLC bought a new position in Heartflow during the 1st quarter valued at about $57,000. Caitong International Asset Management Co. Ltd bought a new position in Heartflow during the 4th quarter valued at about $72,000. Finally, Valeo Financial Advisors LLC acquired a new position in Heartflow in the third quarter valued at about $213,000.

About Heartflow

(Get Free Report)

HeartFlow, Inc is a medical technology company focused on improving the diagnosis and management of coronary artery disease. The company develops software and clinical tools that use artificial intelligence, advanced image analysis and data from coronary computed tomography angiography (CCTA) scans to provide noninvasive assessments of blood flow and potential blockages in the heart.

Its principal product is the HeartFlow Analysis, which creates a personalized, three-dimensional model of a patient's coronary arteries and can estimate the impact of blockages on blood flow.

Further Reading

Insider Buying and Selling by Quarter for Heartflow (NASDAQ:HTFL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Heartflow Right Now?

Before you consider Heartflow, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heartflow wasn't on the list.

While Heartflow currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines